Study #2023-0798
A phase 1/2, open-label study to evaluate the safety, tolerability, pharmacokinetics and efficacy of TNG260 as single agent and in combination with an anti-PD-1 antibody in patients with STK11-mutated advanced Solid Tumors
MD Anderson Study Status
Enrolling
Treatment Agent
TNG260, Pembrolizumab
Description
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non Small Cell Lung Cancer, Solid Tumors, Adult, Endometrial Cancer, Pancreatic Cancer, Cervical Cancer, Breast Cancer, Carcinoma of Unknown Primary
Study phase:
Physician name:
Ferdinandos Skoulidis
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-981-0775
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.